Moreover, the findings were validated in additional cohorts (25 primary tumors) through cell co-culture, cell migration assays, immunofluorescence (IF) staining, flow cytometry, and by analyzing data from The Cancer Genome Atlas (TCGA) database. Our data provides insights into the distinctive ...
Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011;102(1):288-294.PubMedGoogle ScholarCrossref 28. Howitt BE, Jia Y, Sholl LM, ...
kidney cancermanagementHow renal mass biopsy (RMB) impacts patient management with T1 renal masses (T1RMs) is unclear. We explore the association between RMB and utilization of active surveillance (AS), nephron-sparing interventions, and radical nephrectomy (RN).#Data were analyzed retrospectively ...
The BTK signaling pathway is now recognized as one of the most dysregulated pathways in B-cell lymphoproliferative disorders, and it induces several processes required for cancer cell growth, survival, and proliferation.10, 39, 40, 41, 42 Oncogenic activation of BTK signaling represents an absolute...
Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer. 1997;33(3):500–2. CrossRef Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non...
Loss of AID exacerbates the malignant progression of CLL Avery C. Lee Sai Ravi Pingali Chih-Hang Anthony Tang Leukemia(2022) Nature Communications(Nat Commun) ISSN2041-1723(online) Sign up for theNature Briefing: Cancernewsletter — what matters in cancer research, free to your inbox weekly. ...
This work was supported in part by grants from the Fondo de Investigaciones Sanitarias (grant PI11/02399, Fondo Europeo de Desarrollo Regional [FEDER]) and Red Temática de Investigación Cooperativa en Cancer (RTICC; grant RD12/0036/0048, FEDER) of the Instituto de Salud Carlos III (Ministr...
2023, Molecular Cancer Show abstract Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy 2022, Molecular Biomedicine Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials 2022, Signal Transduction and Targeted Therapy Small molecule ...
One case of prostate cancer diagnosed 6 months after 177Lu-lilotomab satetraxetan was not considered to be related. Immunogenicity results The development of a HAMA response after administration of lilotomab and 177Lu-lilotomab satetraxetan was reported for 7 out of 74 subjects overall. Five ...